FY2025 Earnings Forecast for Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Issued By Zacks Research

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Stock analysts at Zacks Research increased their FY2025 earnings per share (EPS) estimates for shares of Ironwood Pharmaceuticals in a research report issued to clients and investors on Wednesday, June 26th. Zacks Research analyst R. Department now forecasts that the biotechnology company will earn $0.72 per share for the year, up from their previous forecast of $0.71. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.56 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q4 2025 earnings at $0.19 EPS and FY2026 earnings at $0.96 EPS.

A number of other research analysts have also weighed in on the company. Craig Hallum reduced their price objective on Ironwood Pharmaceuticals from $18.00 to $14.00 and set a “buy” rating for the company in a research report on Friday, May 10th. StockNews.com raised Ironwood Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, June 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $18.40.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD opened at $6.52 on Monday. Ironwood Pharmaceuticals has a 52-week low of $5.47 and a 52-week high of $15.70. The firm has a market capitalization of $1.02 billion, a P/E ratio of -0.96 and a beta of 0.51. The stock has a 50 day moving average price of $6.75 and a 200-day moving average price of $9.72.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Thursday, May 9th. The biotechnology company reported ($0.02) earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.20). Ironwood Pharmaceuticals had a negative return on equity of 28.45% and a negative net margin of 254.41%. The business had revenue of $74.90 million during the quarter, compared to analysts’ expectations of $105.75 million. During the same quarter last year, the business posted $0.25 EPS. The company’s quarterly revenue was down 28.0% compared to the same quarter last year.

Insider Activity at Ironwood Pharmaceuticals

In other news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the transaction, the director now directly owns 84,207 shares in the company, valued at $535,556.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Catherine Moukheibir sold 44,426 shares of the business’s stock in a transaction dated Thursday, June 6th. The stock was sold at an average price of $6.36, for a total value of $282,549.36. Following the transaction, the director now directly owns 84,207 shares in the company, valued at $535,556.52. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Julie Mchugh sold 22,766 shares of the business’s stock in a transaction dated Monday, June 10th. The shares were sold at an average price of $6.29, for a total value of $143,198.14. Following the completion of the transaction, the director now owns 139,528 shares in the company, valued at $877,631.12. The disclosure for this sale can be found here. 12.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

Large investors have recently made changes to their positions in the company. Old West Investment Management LLC increased its stake in Ironwood Pharmaceuticals by 1.4% during the fourth quarter. Old West Investment Management LLC now owns 56,921 shares of the biotechnology company’s stock worth $651,000 after acquiring an additional 761 shares during the last quarter. Signaturefd LLC increased its stake in Ironwood Pharmaceuticals by 61.4% during the fourth quarter. Signaturefd LLC now owns 2,160 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 822 shares during the last quarter. SummerHaven Investment Management LLC increased its stake in Ironwood Pharmaceuticals by 1.4% during the fourth quarter. SummerHaven Investment Management LLC now owns 68,745 shares of the biotechnology company’s stock worth $786,000 after acquiring an additional 980 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its stake in Ironwood Pharmaceuticals by 10.7% during the fourth quarter. Raymond James Financial Services Advisors Inc. now owns 15,330 shares of the biotechnology company’s stock worth $175,000 after acquiring an additional 1,483 shares during the last quarter. Finally, Texas Permanent School Fund Corp increased its stake in Ironwood Pharmaceuticals by 1.3% during the first quarter. Texas Permanent School Fund Corp now owns 120,245 shares of the biotechnology company’s stock worth $1,047,000 after acquiring an additional 1,557 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.